The abi 1 i ty of bacterial restriction endonuclease to recoqniz specific senuences in DNA makes them a potent tool for dissectio of the human nenome. The oroanization of ribosomal nenes in normal and neoolastic human tissues has been studied by the restriction of ourified DNA. Franrnents of CNA produced bv the restriction endonucleases EcoRI and HindIII were senarated accordinn to size bv anarose nel electronhoresis. DNA franments whi~b~contained ribosomal oenes were identified by hybridization to I-labelled human ribosomal RNA and autoradiopraohy. Analvsis of these studies showed that EcoRI cleaves ribosomal DN from human spleen into frao ents of three sizes (molecular
8'
weiqhts 12, 5, and 4.2 x 10 ) . Dioestion with HindIII yields fraoments of two sizes (molecular weinhts 9.3, and 8.A x 106).
These data oermit the construction of a sinnle map for the human ribosomal qene of 17 x 106 daltons. A similar analvsis of human DNA from several fibroblast and tumor cell lines shows variation onlv at a sinole EcoRI site. Desnite marked alterations in karyotvpe, the oraanization of ribosomal nenes has been stronolv conserved in the neoplastic tissues so far examined.
HETEROZYGOTE EXPRESSION IN PROPIONYL CoA CARBOXYLASE (PCC) DEFICIENCY: DIFFERENCES BETWEEN THE MAJOR COM-PLEMENTATION GROUPS. Barry Wolf and Leon E. Rosenber I~ept. Hum. Gen. and Peds., Yale Univ. Sch. Med., New Haven, CT I PCC deficiency, an autosomal recessively inherited disorder, 1 constitutes at 1 east two major genetic complementation groups (A and C) each characterized by the presence of structurally alterec PCC. We now report studies of PCC activity in tissue extracts from controls and obligate heterozygotes from both complementatic groups. PCC activity in fibroblast extracts from 6 group A heterozygotes was 43-64% of that in control extracts (p<0.001), while activity in 12 group C heterozygotes was indistinguishable from control values. Similar results were obtained using peripheral blood leukocytes. In none of 8 families (5 group C; 3 groul A) in which PCC activity was studied in both parents of an affecl ed child were significant differences observed between parents. Thermostability (45'C) of PCC activity in heterozygotes from bott groups was identical to control. Activities of two other mitochondrial enzymes (6-methylcrotonyl CoA carboxylase and glutamdtc dehydrogenase) were comparable in controls and both groups of ieterozygotes. Whereas the data from group A heterozygotes conforms to expected gene-dose effects, the results from group C leterozygotes are distinctly unusual. Since mamalian PCC is a tetramer, the latter results may reflect any of the following nechanisms: normal PCC activity in tetramers with at least one iormal subunit; an increased proportion of normal subunits due tc increased degradation of mutant subunits; or compensatory synthesis of normal subunits. 
Ska l a) .
A one year old North American Indian boy who presented with episodes of vomiting, lethargy and periodic hypoglycaemia was shown to have hereditary fructose intolerance. A liver biopsy showed typical histological changes and fructose-I-phosphate aldolase activity was greatly diminished.
Although blood fructose increased only slightly during an oral fructose tolerance test, he developed severe hypoglycaemia which did not respond to glucagon. Insulin levels remained low. Plasma lactic acid, uric acid, magnesium, methionine, valine, leucine, isoleucine and aspartate aminotransferase rose during the test while potassium and phosphate fel l marked1 y. Continuous EEG monitoring showed no significant changes, but an ECG showed a slight cardiac arrhythmia when potassium was at its lowest level. Urinary excretion of uric acid and magnesium increased during the fructose load, but there was no. rise in the excretion of potassium, phosphate, or bicarbonate.
Patients with hereditary fructose intolerance may exhibit a Fanconisyndrme and this has been blamed for the falling plasma potassium during a fructose load. The hypokalemic response to acute fructose loading in this patient has been demonstrated not to be due to renal losses. We speculate that potassium probably entered the intracellular space when fructose was administered.
We have used glycine for the acute and chronic management of two newborn infants with isovaleric acidemia. Both infants presented with deep coma and serum isovaleric acid levels in excesr of 50 mg/dl after several days of treatment with parenteral fluids and protein restriction. After administration of intravenous glycine (250 mg/kg/day) the serum isovaleric acid level declined to less than 1 mgldl within 3 days. Restoration of normal clinical status occurred within 6 days. Unexpectedly, the sharp decline of the serum isovaleric acid level was not accompanied by an equally sharp rise of urinary isovalerylglycine excretion. This suggests that in neonates isovalerylglycine may be excreted by the GI tract or that the glycine effect is mediated through a mechanism other than the synthesis of isovalerylglycine. The infants have been treated prophylactically with a low protein diet and oral glycine for 3 and 8 months, respectively. Their psychomotor development has been entirely normal. Neither has suffered a relapse even though the older infant has had several intercurrent infections. Glycine treatment in neonates appears to have aided in the management of the acute toxicity of isovaleric acidemia and may have prevented the reaccumulation of isovaleric acid. Urinary iron excretions with DF and vit. C were evaluated over 48-hour periods in an iron overloaded 9-year-old male with congenital hypoplastic anemia. SQ DF was 85% as effective as I.V. DF. A 12-hour SQ infusion produced the highest excretion during treatment but had a significant effect for 36 hours. Dose response curves were determined for each drug with continuous 12-hour SQ infusions. Using a constant vit. C dose of 500 mg p.o./d and increasing doses of DF, 36 hr. urinary iron increased from 22.5 mg with 1 gm DF to 56.2 mg with 4 gm DF (linear correlation coefficient 0.96, p <0.01). Increasing doses of vit. C (0.5 to 3 gm/d) with a constant DF dose of 2.9 gm were not associated with significant increases in iron excretion (from 44.2 to 49.9 mg) (linear correlation coefficient 0.66, p >0.05).
Continuous EKG and frequent echocardiogram monitoring showed no arrythmias or other changes in cardiac function with doses up to 3 gm vit. C. Our data shows that increased iron excretion continues for 36 hours following 12-hour SQ infusions of DF. A linear increase in excretion occurred with SQ DF doses up to 4 gm. Raising the vit. C dose from 0.5 to 3 gm per day did not result in a significant increase in iron excretion.
